Search alternatives:
ng decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ng decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
6081
-
6082
-
6083
Supplementary Material for: Prevalence of Driving and Traffic Accidents among People with Seizures: A Systematic Review
Published 2019“…<b><i>Background and Objectives:</i></b> Epilepsy influences the ability to drive. We undertook a systematic review to determine the prevalence of driving or holding a driver’s license among people with seizures, the prevalence of traffic accidents among those who drive, and factors that may explain heterogeneity in these point estimates. …”
-
6084
Thermoconformational Behavior of Cellulose Nanofiber Films as a Device Substrate and Their Superior Flexibility and Durability to Glass
Published 2021“…Yet, this concept is still in its infancy. In this work, we report the extraordinary durability of thin molecular interlayered organic flexible energy devices based on chemically tuned cellulose nanofiber transparent films that outperform glass by decreasing the substrate weight by 50%. …”
-
6085
Efficacy of SGLT2 inhibitors for anthracycline-induced cardiotoxicity: a meta-analysis in cancer patients
Published 2024“…</p> <p><b>Results:</b> 3 cohort studies were identified, analyzing 2817 patients. Results display a significant reduction in overall mortality [RR = 0.52 (0.33–0.82); <i>p</i> = 0.005; I<sup>2</sup>= 32%], HF hospitalization [RR = 0.20 (0.04–1.02); <i>p</i> = 0.05; I<sup>2</sup>= 0%] and no significant reduction in HF incidence [RR = 0.50 (0.20–1.16); <i>p</i> = 0.11, I<sup>2</sup>= 0%].…”
-
6086
A Biomimetic Interface with High Adhesion, Tailorable Modulus for On-Skin Sensors, and Low-Power Actuators
Published 2019“…By adopting this interface, we successfully fabricate a soft (skin-like modulus 0.1–10.0 MPa), ultrathin (∼50 μm), self-adhesive, and skin-compliant sensor. …”
-
6087
A Biomimetic Interface with High Adhesion, Tailorable Modulus for On-Skin Sensors, and Low-Power Actuators
Published 2019“…By adopting this interface, we successfully fabricate a soft (skin-like modulus 0.1–10.0 MPa), ultrathin (∼50 μm), self-adhesive, and skin-compliant sensor. …”
-
6088
A Biomimetic Interface with High Adhesion, Tailorable Modulus for On-Skin Sensors, and Low-Power Actuators
Published 2019“…By adopting this interface, we successfully fabricate a soft (skin-like modulus 0.1–10.0 MPa), ultrathin (∼50 μm), self-adhesive, and skin-compliant sensor. …”
-
6089
A Biomimetic Interface with High Adhesion, Tailorable Modulus for On-Skin Sensors, and Low-Power Actuators
Published 2019“…By adopting this interface, we successfully fabricate a soft (skin-like modulus 0.1–10.0 MPa), ultrathin (∼50 μm), self-adhesive, and skin-compliant sensor. …”
-
6090
A Biomimetic Interface with High Adhesion, Tailorable Modulus for On-Skin Sensors, and Low-Power Actuators
Published 2019“…By adopting this interface, we successfully fabricate a soft (skin-like modulus 0.1–10.0 MPa), ultrathin (∼50 μm), self-adhesive, and skin-compliant sensor. …”
-
6091
A Biomimetic Interface with High Adhesion, Tailorable Modulus for On-Skin Sensors, and Low-Power Actuators
Published 2019“…By adopting this interface, we successfully fabricate a soft (skin-like modulus 0.1–10.0 MPa), ultrathin (∼50 μm), self-adhesive, and skin-compliant sensor. …”
-
6092
A Biomimetic Interface with High Adhesion, Tailorable Modulus for On-Skin Sensors, and Low-Power Actuators
Published 2019“…By adopting this interface, we successfully fabricate a soft (skin-like modulus 0.1–10.0 MPa), ultrathin (∼50 μm), self-adhesive, and skin-compliant sensor. …”
-
6093
DataSheet1_Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia.pdf
Published 2023“…A biochemical assay using a purified Artemis:DNA-PKcs complex shows that the Artemis inhibitors 827171, 827032, 826941, 825226 have nanomolar IC50 values for Artemis inhibition. …”
-
6094
DataSheet1_Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia.docx
Published 2023“…A biochemical assay using a purified Artemis:DNA-PKcs complex shows that the Artemis inhibitors 827171, 827032, 826941, 825226 have nanomolar IC50 values for Artemis inhibition. …”
-
6095
DataSheet1_Effect of blueberry intervention on endothelial function: a systematic review and meta-analysis.ZIP
Published 2024“…A significant decrease in diastolic blood pressure (DBP) was also observed (MD: −2.20 mm Hg; 95% CI: −4.13, −0.27; I<sup>2</sup> = 11%). …”
-
6096
Supplementary Material for: Effects of Low-Volume, High-Intensity Interval Training Compared with Continuous Training on Regional and Global Body Composition in Adults with Metabol...
Published 2021“…<b><i>Methods:</i></b> This is a post hoc analysis of the randomized clinical trial Intraining-MET. …”
-
6097
-
6098
-
6099
Frequency trajectories of iSNVs that fluctuated (Top) and their positions on the genome (Bottom) (patients A-I).
Published 2025“…<p>The inclusion criterion was iSNVs that changed from below 50% at Baseline (i.e., 0 days post baseline), to above 50% at PT12 (12 weeks post treatment), and decreased to below 50% at PT24 (24 weeks post treatment). …”
-
6100
Table_2_Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome.XLSX
Published 2022“…Background<p>Irritable bowel syndrome (IBS) is a highly prevalent chronic pain disorder with multiple underlying mechanisms and few treatments that have been demonstrated to be effective in placebo controlled trials. …”